Company ProfilePremium

Bukwang Pharmaceutical Co., Ltd.

Company Profile Analysis

부광약품주식회사

ESOMAR 23 Corporate BadgeISO Certifications Badge
Bukwang Pharmaceutical Co., Ltd. - Company showcase

Year Founded & Workforce

1960

611 Employees

Bukwang Pharmaceutical Co., Ltd. logo

Bukwang Pharmaceutical Co., Ltd. Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Bukwang Pharmaceutical Co., Ltd. Overview

Bukwang is a 66-year-old, mid-sized Korean prescription-drug company. In 2022 it moved from founder-family control to the OCI Group, and the business now runs on three engines. The first is a domestic ETC franchise led by diabetic-neuropathy products (Dexid and Thioctacid), liver therapy (Legalon) and iron supplementation (Feroba). The second is a fast-growing CNS franchise built around in-licensed lurasidone (Latuda, launched August 2024), with Exel, Zaledeep, Orfil and the 2026 epilepsy launch Bukwang Brivil alongside it. The third is a Copenhagen-based discovery subsidiary, Contera Pharma, which combines a Phase 2-ready Parkinson's asset (CP-012) with an oligonucleotide/RNA discovery platform validated by an October 2025 research option deal with H. Lundbeck. After two loss years (FY2022–23) and a deep restructuring, Bukwang posted record revenue of KRW 200.7bn in FY2025 and raised KRW 89.3bn of equity. It then bought a court-rehabilitated manufacturer to relieve chronic capacity shortfalls. Management targets KRW 600bn revenue and a top-20 domestic ranking by 2030.


What the company does

Bukwang develops, manufactures, in-licenses and sells finished pharmaceuticals in Korea. Dosage forms include oral solids, injectables, oral solutions, topical solutions and ointments, plus quasi-drugs such as toothpaste [company/aggregator descriptions; IR FY2025]. The company describes its business as making and selling medicines and quasi-drugs. Its stated management philosophy is to contribute to a stable supply of medicines and serve society through high-quality production, with an ambition to become a global pharma-bio company [IR FY2025 Fact Book, "Vision"]. Bukwang calls its R&D model "Global Open Innovation". In practice that means subsidiaries, joint ventures, research collaborations, equity investments and fund commitments, focused on CNS and oncology [IR FY2025].

Business model and revenue model

Product sales dominate: Revenue is almost entirely product sales to wholesalers, hospitals and pharmacies in Korea. Manufactured products ("제품") sit alongside traded and co-promoted goods ("상품"). An aggregator breakdown of Q2 FY2026 revenue shows other manufactured products 31%, merchandise (traded goods) 22%, Dexid 9%, Feroba 7% and Latuda 7% [butler.works, sourced from DART, Q2-2026].

Licensing and collaboration revenue is emerging: Contera Pharma booked about KRW 10.7bn in FY2025, believed to be largely the Lundbeck upfront payment [Dealsite, Jun-2026]. Further Lundbeck research funding was recognised in Q2 FY2026 [Dailypharm, Jul-2026]. Future milestones and royalties are possible.

Contract manufacturing (CMO) is nascent: Bukwang Unipharm (formerly Korea Union Pharm) began contract-making Bukwang products in June 2026. Management has said a synthetic-drug CDMO business is a medium-term option once capacity stabilises [Dealsite, Jun-2026; Medigatenews, Jul-2026].

Co-promotion: Since 1 April 2026 Bukwang co-promotes Servier Korea's Acertil and Vastinan brands (7 SKUs), covering hospitals and clinics under 300 beds [Dailypharm, Mar-2026].

Exports are immaterial: An aggregator shows FY2025 export revenue of KRW 0.7 x 100M [valueline.co.kr]. Overseas revenue in practice comes from Contera's collaboration income.

No subscription model: ### Value-chain position

Bukwang is an integrated, domestic-market finished-dose company. It covers formulation R&D and in-house incrementally modified drugs (IMDs, "개량신약"), in-licensing of foreign originals, manufacturing at Ansan (and Wonju from 2026), and specialty sales forces. It does not produce APIs at scale; raw-material supply problems hit certain antivirals in 2023 [IR FY2023]. Since 2023 the Ansan plant has run above 100% utilisation (115% in Q1-2026; 122% average in late 2025). About 20% of FY2025 revenue relied on outsourced production [Dailypharm, May-2026; Dealsite, Jun-2026].

Customers and end-markets

Customers: pharmaceutical wholesalers, tertiary and general hospitals, psychiatric hospitals, clinics, pharmacies (OTC and toothpaste) and, through Contera, global pharma partners (Lundbeck).

Therapeutic end-markets: diabetic neuropathy and complications; CNS (schizophrenia, bipolar depression, depression, insomnia, epilepsy, dementia); hepatology (Legalon, Regadex, legacy hepatitis-B antivirals); haematology/nutrition (Feroba); gastroenterology (Selbex, pancreatin combination); cardiovascular and metabolic (Servier co-promotion, Eroset, Budiang); consumer health (Tacenol, Sirinmed toothpaste).

Independent characterisation

Bukwang is a turnaround and re-rating story inside a chemical conglomerate's pharma ambitions. The ETC base is steady and low-growth; the 2025 jump came mainly from recovered supply of the thioctic-acid franchise and the Latuda launch. Underneath sit a capacity bottleneck now being fixed through acquisition, and an option-like R&D subsidiary. Contera has consumed about KRW 120bn of Bukwang capital over 12 years [Dealsite, Jun-2026] and only in 2025 produced external validation. Group-level questions also bear on the equity story: OCI Holdings' need to reach 30% ownership by September 2027 and its own solar-sector exposure.

Strategy

Stated strategy (paraphrased from FY2025 IR, AGM 2025/2026 and investor calls)

  1. Top-20 domestic pharma by 2030. Target revenue of KRW 600bn and double-digit operating profit [Dealsite Jun-2026, citing the Mar-2026 AGM]. Levers are IMDs, first generics and global new-drug pipelines.

  2. Become a CNS specialist. Expand Latuda (first-line bipolar positioning, higher-dose schizophrenia use, paediatric psychiatry, MDD label extension) and add launches (Brivil, Circadeep, Ariplus).

  3. Fix supply. Add capacity (Ansan automation, the Union/Unipharm acquisition, MES) to end recurring stock-outs and cut outsourcing costs. Use surplus capacity for CMO/CDMO later.

  4. R&D "selection and concentration". Prioritise CP-012 and the RNA platform. Wind down Protekt and Dyna. Spin the RNA business into a new Danish company to attract outside VC and make an M&A exit easier [Dealsite Nov-2025; Edaily].

  5. Shareholder returns. Interim and quarterly dividends. Met Korea's "high-dividend company" test for FY2025, making separate dividend taxation available to shareholders [Medigatenews Mar-2026]. Earlier statements mentioned treasury-share buyback and cancellation [Medifonews Mar-2025].

Initiatives in the last 24 months

DateInitiativeDetail / targets
Mar–Jul 2025KRW 89.3bn rights offeringUse of proceeds: manufacturing expansion KRW 34bn (38%); new equipment KRW 8.6bn (10%; solid-dose line KRW 7.1bn, MES KRW 1.5bn); acquisition of a manufacturer KRW 30bn (34%); R&D working capital KRW 16.7bn (18%). Original KRW 100bn plan: plant KRW 49.5bn, acquisition KRW 35bn, R&D KRW 30bn [Kukinews Apr-2025; IR Q1-26]
2,025CNS sales force expansionLarger specialist team for Latuda coverage
Oct 2025Lundbeck RNA collaboration (Contera)Two Lundbeck-chosen targets; upfront, full research funding per target, milestones, tiered royalties
Nov 2025RNA subsidiary planCNS-focused RNA company in Denmark; talks with overseas VCs; Danish tax pre-approval filed in Q1-26; completion targeted Q4 2026
2025–2026Shareholder returnsKRW 50 interim (Nov 2025) plus KRW 75 final; total KRW 12.3bn, about 98% payout
Dec 2025 – Oct 2026Union Pharm acquisition and integrationBoard replaced (Jun 2026); rehabilitation ended (31 Aug 2026); renamed Bukwang Unipharm (8 Oct 2026); production transfers (pancreatin combination, Hard Chewable)
Q1 2026KRW 50bn fund commitmentBukwang to anchor a KRW 50bn bio fund run by QUAD as strategic investor
Mar 2026Servier co-promotionCardiovascular adjacency
May 2026AI/organoid MOUWith Dream CIS (CRO; organoid NAMs) and AWS (cloud/AI): joint pilot on organoid toxicity plus AI analytics, AI trial design, regulatory science
2,026Latuda MDD Phase 3IND approved; about two-year study
2,026CP-012 Phase 2Global IND filed; about two-year programme; topline Q1 2028

ESG commitments. ISO 14001 and ISO 45001 certified. Mid- to long-term carbon-neutrality target disclosed (details NPD). Human-rights impact assessment. Fair-trade compliance programme [IR FY2025].

Guidance

FY2026: operating profit to be volatile because of CP-012 Phase 2 spend and the Lundbeck base effect, but the company aims to stay profitable [CEO, Q1-26 call]. Gradual margin recovery from H2 2026 [Q2-26 call].

Medium term: KRW 600bn revenue by 2030.

  • No numerical FY2026 revenue guidance was found (NPD).

Products & Services

Prices are set by Korea's National Health Insurance reimbursement for ETC products and are not disclosed product by product in the sources reviewed (NPD). The catalog lists named products identified in company disclosures and trade press. It is not exhaustive: Bukwang's full ETC list runs to dozens of SKUs.

Diabetic neuropathy / metabolic franchise (core cash generator)

ProductMolecule / typeIndicationOrigin / yearNotes
Dexid (덱시드)Thioctic acid tromethamine (R-enantiomer IMD)Diabetic polyneuropathyIn-house IMD (2010s)Largest single product: KRW 4.6bn in Q1-26; about 9% of revenue [Dealsite Jun-2026; butler.works]; export deals with five Southeast Asian countries [IR 2Q18]
Thioctacid / Thioctacid HRThioctic acidDiabetic polyneuropathyLaunched 1998 / HR 2003KRW 2.4bn in Q1-26. Dexid + Thioctacid revenue +181% (FY2024) and +43% (FY2025), driven by recovered supply [Bizwatch; IR FY2025]
Budiang (부디앙)Empagliflozin (generic)Type 2 diabetesOct 2025New chronic-disease launch [Sidae Oct-2025]
Eroset (에로젯정 1/10mg)Pitavastatin + ezetimibeHypercholesterolaemia / mixed dyslipidaemiaAug 2026Low-dose statin combination [Dailian Aug-2026]

CNS franchise (growth engine; "CNS Business Division" set up 2024)

ProductMoleculeIndicationOrigin / yearNotes
Latuda (라투다정)Lurasidone HClSchizophrenia; bipolar I depressionSumitomo Pharma licence (Apr 2017); MFDS approval Nov 2023; launched Aug 2024FY2025 sales KRW 11.0bn; monthly sales above KRW 1bn from May 2025; 44/47 tertiary hospitals coded; prescribed at 139 general hospitals, 120 psychiatric hospitals and 1,034 clinics; ranked 6th in the schizophrenia/bipolar market in Q4-25 [IR FY2025]. Q1-26 outpatient prescriptions +153% YoY [IR Q1-26]. MDD adjunct Phase 3 IND approved (disclosed 2 Jun 2026)
Exel (익셀)Antidepressant (company CNS portfolio)DepressionIn-licensed (NPD)FY2025 +11.3% [IR FY2025]
Zaledeep (잘레딥)HypnoticInsomniaPortfolio productFY2025 +33.6%; Q1-26 +30%
Circadeep / Circadeep SR (서카레딥)MelatoninInsomniaQ4 2025 / Q1 2026New launches [Sidae Oct-2025; IR Q1-26]
Lonasen (로나센)AntipsychoticSchizophreniaPortfolio productListed among core CNS products [IR FY2025]
Orfil family (오르필 ER, syrup, injection)ValproateEpilepsy (first-line)Portfolio productFY2025 +5.9%; Q1-26 +14%
Bukwang Brivil (부광브리필정)Brivaracetam (3rd-generation AED)Epilepsy (focal seizures)In-house institute; launch symposium 14–15 Mar 2026Reimbursement expected around June 2026 [Medifonews Mar-2026]
Ariplus (아리플러스)Dementia combinationAlzheimer's dementiaQ2 2025Neurology launch [Dealsite Apr-2025]

Hepatology / gastroenterology / haematology

ProductMoleculeIndicationNotes
Legalon (레가론)Silymarin (milk thistle)Liver cirrhosis / hepatocyte supportKRW 3.5bn in Q1-26; reimbursement retained (2026 priority) [IR FY2025; Dealsite]
Regadex (레가덱스)Ursodeoxycholic acid + biphenyl dimethyl dicarboxylateLiver functionH2 2025 launch
Feroba-U SR (훼로바)Oral ironIron deficiencyKRW 3.9bn in Q1-26; about 7% of revenue
Selbex (셀벡스)TeprenoneGastritisQ1-26 prescriptions +104%
Dilastin (딜라스틴)NPDNPDQ1-26 prescriptions +16%
Complex Pazyme (복합파자임이중정)Pancreatin combinationDigestiveFirst product made at Union/Unipharm (shipped Jun 2026)
Levovir (레보비르)ClevudineChronic hepatitis B2006 Korean new drug; legacy
Bukwang Adefovir; Taprid; EntecavirNA antiviralsHepatitis BLegacy antiviral line; API supply issues in 2023

Cardiovascular (co-promotion since 1 Apr 2026)

ProductMoleculeIndicationArrangement
Acertil 4/8mgPerindopril tert-butylamineHypertensionServier Korea co-promotion; Bukwang alone covers clinics under 100 beds and co-covers 100–299 beds
Acertil Arginine 5/10mgPerindopril arginineHypertensionSame
Acertil Plus ArgininePerindopril arginine + indapamideHypertensionSame
Vastinan / Vastinan MRTrimetazidine HClStable angina (add-on)Same
Addtamin; LodivanNPDChronic diseaseNew launches, Q2 2026 [IR Q1-26]

Consumer health / OTC / quasi-drugs

ProductCategoryNotes
Tacenol (타세놀)Acetaminophen analgesic/antipyreticCOVID-era demand driver [Dealsite 2022]
Sirinmed (시린메드)Sensitive-teeth toothpasteTrademark since 2005; toothpaste manufacturing partly outsourced [IPqwery; Dealsite Apr-2026]
Hard Cal-C Plus; Hard Chewable / Chewable EasyVitamin/mineral (ViC) OTCsProduction moving to Unipharm from Sep 2026
Ozanex cream (오자넥스)Antibiotic ointmentLaunched 2022

Development portfolio (see §13 for detail)

AssetOwnerIndicationStage (Oct-2026)
Lurasidone (new indication)BukwangMDD adjunctKorean Phase 3 IND approved; topline targeted Q1 2028; final CSR H1 2028
CP-012ConteraParkinson's morning akinesia ("early-morning OFF")Global Phase 2 IND filed (80 patients, 25 sites, US + Poland/Italy/Spain)
CP-102ConteraCanavan disease (NAT8L-targeting ASO)Preclinical; 28-week NHP data Apr 2026
CP-10XConteraChronic kidney diseaseExploratory
Lundbeck targets (2)Contera / Lundbeck optionUndisclosed neurological diseasesDiscovery
BUK-001BukwangParkinson's diseaseCandidate selection, H1 2026
AhR antagonistJaguAhRSolid tumoursUnder review
Controlled-release IMD (CNS)BukwangCNS (undisclosed)Pilot clinical study
Long-acting injectablesBukwang (+ partners)NPDResearch

Financial Narrative

Income statement (consolidated, KRW 100M unless stated)

Margins (%, derived):

Revenue CAGR FY2021–FY2025: 2.4% (derived). From the FY2023 trough to FY2025 the CAGR is 26.3%.

Quarterly trajectory (consolidated, KRW 100M):

[IR Q1-26 quarterly chart; Dealsite/Medigatenews.] 2Q25 operating profit was KRW 21 x 100M in the July 2025 release. H1-2026 revenue was KRW 104.8bn (+15.9%), the first half-year above KRW 100bn, while operating profit was KRW 2.5bn (−49.9%).

Commentary: trends, inflections and drivers.

  1. FY2022 inflection to losses. The parent stayed profitable (separate operating profit of KRW 12.3bn), but Contera's R&D for the JM-010 Phase 2 programmes in the US, EU and Korea more than doubled. Derivative valuation losses on Contera's financial-investor contracts and mark-downs on listed investments such as Acer Therapeutics pushed net loss above operating loss [IB Tomato Mar-2023; Dealsite Jul-2022].

  2. FY2023 trough. This was largely self-inflicted and partly cosmetic. Under OCI's active involvement from Q3 2023, the company cut credit sales, shortened receivable terms, cut channel inventory, tightened distributor margins, pruned low-margin products and accepted returns while consolidating wholesalers. API supply problems in antivirals and the fading of COVID-related demand added to the decline [IR FY2023]. Receivables fell from KRW 78.0bn (3Q22) to KRW 58.3bn (3Q23), then to about KRW 23.4bn (3Q24); receivable days improved from 101 to 56 [Dailypharm Nov-2024].

  3. FY2024 recovery. Supply of the thioctic-acid franchise recovered (+181%), CNS strategic products grew 42%, Latuda launched in August, and cost cuts took effect. The return to a small operating profit was the first since FY2021 [Bizwatch Feb-2025].

  4. FY2025 record. Revenue was KRW 200.7bn and operating profit KRW 14.1bn (+775%). Drivers were Dexid/Thioctacid (+43%), CNS strategic products (+91% against a 7.4% market), Latuda (KRW 11.0bn), Bukwang Medica and the Lundbeck upfront. Parent operating profit actually fell 5.5% to KRW 16.1bn on symposium and marketing spend; the consolidated improvement came from subsidiaries turning profitable [IR FY2025].

  5. FY2026 year to date: margin compression. Higher outsourced production (to prevent stock-outs), FX-driven input costs, launch marketing, the absence of a Lundbeck upfront and early CP-012 Phase 2 spend cut H1 operating margin to about 2.4% [IR Q1-26; Medigatenews Jul-2026]. Management guides to gradual normalisation in H2.

Balance sheet (consolidated, KRW 100M)

Sources and notes. IR FY2023 and FY2025 Fact Books. The DART-based aggregator valueline shows FY2025 cash and equivalents of 962 plus short-term financial instruments of 1,200, which sum to the IR's 2,162. FY2021 balance sheet is NPD in sources reviewed. The KRW 80bn of borrowings arose in FY2023 and was described as long-term; its FY2024–25 short/long split is NPD. Goodwill is not separately disclosed. Working capital cannot be computed because current liabilities are not split out in IR materials (NPD).

Commentary. The KRW 89.3bn rights offering (July 2025) lifted equity by about KRW 97.5bn and left the group in net cash of about KRW 136bn at FY2025 year end. Roughly KRW 30bn of that went into Union in May 2026, and planned capex at Ansan (KRW 34bn facility expansion plus KRW 8.6bn equipment) is still mostly unspent. Q1-26 aggregator data show cash of 1,144 plus short-term instruments of 970 [valueline].

Cash flow (consolidated, KRW 100M)

Commentary. OCF was negative in FY2023 because inventory rose during the trade restructuring. FY2024 OCF of KRW 34.4bn reflects the collection of about KRW 52bn of receivables. FY2025 OCF moderated as inventories grew with sales and outsourced production.

Ratios (derived from the tables above)

Notes.

  • FY2022 averages need FY2021 balances (NPD).

  • ROIC is NPD: tax and invested-capital detail is not available.

  • Current ratio is NPD: current liabilities are not disclosed in IR.

  • Net debt/EBITDA is not meaningful because the group is in net cash.

  • Interest coverage is NPD: interest expense is not disclosed. With KRW 80bn of borrowings and FY2025 EBIT of KRW 14.1bn, coverage is probably comfortable, but it cannot be verified.

  • Payables include "other payables", which distorts the FY2023 figure.

  • Aggregators show TTM ROE of 4.1–4.2% (valueline/StockHub, mid-2026), consistent with the table.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Group Entities

EntityCountryBukwang stakeFunctionStatus

Bukwang Pharmaceutical (parent)

Korea

—

ETC, OTC, CNS, manufacturing (Ansan)

Operating

Bukwang Medica Co., Ltd.

Korea

Consolidated (stake NPD)

Consumer health / OTC distribution

Operating; revenue up about 40% YoY in Q2-26 [Dailypharm Jul-2026]; sold Ansan Banwol site and KGMP facility in 2025 [KIRS]

Contera Pharma A/S

Denmark

99.9% (Q4-25) → 100% (Q1-26)

CNS small-molecule (CP-012) and RNA/oligo discovery

Operating; RNA spin-off pending

JaguAhR Therapeutics

Singapore

75.02%

AhR antagonist (immuno-oncology)

Partner ASLAN liquidated (17 Jul 2024); follow-on direction under review

Protekt Therapeutics

Israel

96.53%

Neurodegeneration (PKR inhibitor)

Liquidation begun Q1-2026

Dyna Therapeutics

Korea

—

SOL-804 (prostate cancer)

Liquidated (date NPD)

Bukwang Unipharm (ex-Korea Union Pharm)

Korea (Wonju)

75.14%

Solids, liquid injections, cephalosporin powder injections

Consolidated from about Q2/Q3-2026; renamed 8 Oct 2026

Revenue by Segment (KRW) and Segment Margins & Growth (%)

MetricFY2021FY2022FY2023FY2024FY2025

Consolidated revenue (KRW 100M)

1,8251,9091,2591,6012,007

Parent (separate) revenue (KRW 100M)

1,8161,9031,2521,5761,673

Subsidiaries net of eliminations, revenue (KRW 100M, derived)

96725334

Parent operating profit (KRW 100M)

132123-166170161

Consolidated operating profit (KRW 100M)

56-2-36416141

Gap: subsidiaries' net operating drag (KRW 100M, derived)

-76-125-198-154-20

Parent operating margin (%)

7.36.5-13.310.89.6

Parent revenue contribution to group (%)

99.599.799.498.483.4

Segment Margins & Growth (%)

MetricFY2022FY2023FY2024FY2025

Consolidated revenue growth (%)

4.6-34.027.225.4

Parent revenue growth (%)

4.8-34.225.96.1

Income Statement (KRW) and Margin Analysis (%)

MetricFY2021FY2022FY2023FY2024FY2025

Revenue (KRW 100M)

1,8251,9091,2591,6012,007

Revenue growth YoY (%)

7.54.6-34.027.225.4

Cost-of-sales ratio (%)

58.558.462.653.654.2

Gross profit (KRW 100M, derived)

757794471743919

R&D cost (KRW 100M)

225243342284262

R&D / revenue (%)

12.312.727.217.713.0

Operating profit (KRW 100M)

56-2-36416141

EBITDA (KRW 100M)

10340-324——

Net income, consolidated (KRW 100M)

-28-42-344-35126

Net income attributable to owners (KRW 100M)

-9-25-313-26126

Basic EPS (KRW)

-13-36-458-39152

Cash DPS (KRW)

100000125

Margin Analysis (%)

MetricFY2021FY2022FY2023FY2024FY2025

Gross margin (%)

41.541.637.446.445.8

Operating margin (%)

3.1-0.1-28.91.07.0

EBITDA margin (%)

5.62.1-25.7——

Net margin, consolidated (%)

-1.5-2.2-27.3-2.26.3

Financial Analysis

Metric1Q252Q253Q254Q251Q262Q26

Revenue (KRW 100M)

478426478625478570

Operating profit (KRW 100M)

302010821114

Net income (KRW 100M)

-164——1214

Balance Sheet (KRW) and Margin Analysis (%)

MetricFY2022FY2023FY2024FY2025

Total assets (KRW 100M)

4,0094,2933,7314,774

Current assets (KRW 100M)

2,1872,5172,0373,061

Cash, equivalents and short-term deposits (KRW 100M)

8551,5291,3012,162

Trade receivables (KRW 100M)

880357236278

Inventories (KRW 100M)

386569417522

PP&E (KRW 100M)

1,2191,211——

Intangible assets (KRW 100M)

7088——

PP&E + intangibles (KRW 100M)

1,2891,2991,4671,488

Investments in funds/shares (KRW 100M)

198197167162

Borrowings, total (KRW 100M)

0800800800

Trade and other payables (KRW 100M)

16524176232

Total liabilities (KRW 100M)

1,2911,9781,2901,358

Total equity (KRW 100M)

2,7182,3152,4413,416

Liabilities / equity (%)

47865340

Net debt, negative = net cash (KRW 100M, derived)

-855-729-501-1,362

Cash Flow (KRW)

MetricFY2021FY2022FY2023FY2024FY2025

Operating cash flow (KRW 100M)

265165-105344185

Dividends paid in year (KRW 100M)

——0049

Share cancellation, book value (KRW 100M)

0005000

Returns & Leverage Ratios (%) and Financial Ratios (x)

MetricFY2022FY2023FY2024FY2025

ROE on average equity (%)

—-13.7-1.54.3

ROA on average assets (%)

—-8.3-0.93.0

Debt / equity (%)

0.034.632.823.4

Asset turnover on average assets (x)

—0.300.400.47

Receivable days (year-end)

1681035451

Inventory days on COGS (year-end)

126264177175

Payable days on COGS (year-end)

54117578

Cash conversion cycle (days, approximate)

240356156148

Region (KRW 100M) Overview

Region (KRW 100M)FY2025

Korea, all product and other revenue (KRW 100M, derived)

1,900

Denmark, Contera collaboration revenue (KRW 100M)

107

Product exports from Korea (KRW 100M, aggregator)

1

Dosage Form Details

Dosage form (KRW 100M)FY2025

Film-coated tablets

838

Plain tablets

246

Capsules

239

Sugar-coated tablets

13

Injectables

91

Valuation Multiples (KRW)

MetricFY2022FY2023FY2024FY2025

Year-end share price (KRW)

7,9985,5764,1963,785

Year-end market cap (KRW 100M)

6,2184,3353,1423,734

Capital Markets

MetricBukwangWhaninSamjinBoryung

P/E TTM (x)

46.79.110.66.4

P/B (x)

1.230.440.820.86

Dividend yield (%)

3.03.04.31.8

EV/Sales FY2025 (x, derived)

1.36

NPD

NPD

NPD

EV/EBITDA (x)

NPD

NPD

NPD

NPD

Analyst Conclusions

Management guidance

  • FY2026: profitable but volatile operating income; H2 margin normalisation; Unipharm synergies; CP-012 Phase 2 start; RNA NewCo by Q4 2026.

  • 2030: KRW 600bn revenue (about 3x FY2025) and a top-20 ranking.

  • No numerical FY2026 revenue or earnings guidance; no sell-side consensus.

Bull case

  1. CNS compounding. Latuda grew 153% in Q1-26 prescriptions and holds 44/47 tertiary hospital codings. Add a possible MDD label in 2028 and new launches (Brivil, Circadeep), and CNS could become a KRW 50bn-plus franchise, re-rating Bukwang towards specialist peers.

  2. Capacity unlock. Unipharm adds about 30% solid capacity and about 2x injectables. Insourcing about 20% of revenue now made by third parties should recover gross margin lost to outsourcing (consolidated COGS ratio rose from 56.3% to 60.2% YoY in Q1-26).

  3. R&D optionality at low cost. A positive CP-012 Phase 2 (topline Q1 2028) or a funded RNA NewCo with further Lundbeck milestones could produce non-dilutive value well above Contera's book value. OCI's 30% requirement adds a technical bid.

Bear case

  1. Margin structure. Even at record revenue, FY2025 operating margin was only 7%, and H1-26 fell to about 2.4%. The 2030 double-digit margin target looks distant, and P/E of about 47x already discounts a recovery.

  2. Execution risk on a distressed asset. Unipharm ran at 29% utilisation, was capital-impaired and delisted. Normalisation costs and possible extra funding needs could absorb cash, as flagged when the deal was announced.

  3. R&D track record. JM-010, Protekt, Dyna and SOL-804 all failed or were abandoned after heavy spending. CP-012 Phase 2 is small and the Lundbeck economics are undisclosed. The March 2026 spike (+154% year to date) and subsequent −55% show how sentiment-driven the RNA narrative is.

Catalysts and monitorables (next 12 months)

  • Q3-26 results (late Oct 2026) and Q4/FY2026 results (Feb 2027): margin recovery against outsourcing costs.

  • Approval and first patient dosed in the CP-012 Phase 2 (US/EU).

  • Formation and outside funding of the RNA NewCo (Q4 2026); any Lundbeck milestone or target-option news; a CP-102 partnering deal.

  • Unipharm: transfer of production, first external CMO contracts, path to break-even.

  • Latuda MDD Phase 3 enrolment; quarterly Latuda prescription data (UBIST).

  • OCI Holdings' actions on the 30% requirement (deadline Sep 2027).

  • Dividend declarations (interim and quarterly) and maintenance of high-dividend status.

  • Korean drug-price reform implementation.

Analyst verdict

Bukwang Pharmaceutical is no longer the founder-run, R&D-dispersed company that drifted into losses in 2022–23. Under OCI it has become a leaner, better-capitalised domestic specialist. The core business is now clean: receivable days have roughly halved, channel inventory has been reset and the group holds net cash. Growth is real. Revenue rose from KRW 125.9bn in FY2023 to a record KRW 200.7bn in FY2025, and H1-2026 continued at +16%. That growth comes from a credible CNS franchise and a recovered thioctic-acid line rather than one-off items, although FY2025 profit did benefit from the Lundbeck upfront.

Profitability is where the case is unresolved. The company has spent three years running a plant beyond nameplate capacity and buying third-party production to avoid stock-outs. That cost explains most of the H1-2026 margin compression and is exactly what the Unipharm acquisition is meant to fix. If insourcing works through 2027, operating margins should move back above high single digits without heroic assumptions. If integration stalls, Bukwang remains a low-margin distributor of other companies' molecules trading at a specialist multiple.

The equity therefore splits into two parts. One is a domestic franchise that at peer multiples (P/E around 10x, P/B under 1x) would justify a materially lower valuation than today's. The other is an option on CP-012 and the Contera RNA platform, which the market prices on news flow, as the round trip from roughly KRW 3,800 to 9,890 and back to about KRW 4,100 in 2026 shows. The sponsor overlay (OCI's 30% deadline) offers technical support but does not change fundamentals. Overall, Bukwang is an improving but not yet proven operating story with asymmetric but binary R&D upside. Evidence of margin recovery from Unipharm and a dosed CP-012 Phase 2 are the two signals that would justify the current premium.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Board of Directors

NameTitleTenure (approx.)Background

Ahn Mi-jung (안미정)

Chairman; inside director

Board since 26 Mar 2025

Representative patent attorney at Jipyong patent firm; adjunct professor of materials science, Yonsei University; OCI Holdings board chair from Mar 2024 (first woman outside-director chair in OCI Group); former outside director of Genexine and Medipost [Medigatenews Mar-2025]

Lee Je-young (이제영)

CEO (representative director)

CEO since 2024 per IR (sources conflict: Dealsite says Mar 2023, TheGuru says Mar 2024; IR materials list Lee Woo-hyun as CEO at Dec 2023 and Lee Je-young by Apr 2024)

Former public prosecutor (17 years); joined OCI 2019; executive VP, OCI Holdings strategy office, led OCI's holding-company conversion [TheGuru]

Kim Sung-soo (김성수)

Executive VP, Head of Business

Since 2024 (earlier Head of Management Strategy)

Appointed inside director of Bukwang Unipharm, Jun 2026

Sung Kwang-hyun (성광현)

Executive VP, Union Acquisition TF; representative director of Bukwang Unipharm

2,026

Ex-OCI Holdings

Kim Min-gyu (김민규)

Head of Management Strategy; filing officer

2025–2026

Signatory on the H1-2025 semi-annual report

Kim Ji-heon (김지헌)

Head of R&D

Joined 2023

Advocates disciplined portfolio pruning

Lee Sang-gil (이상길)

Outside director; audit committee

Since Mar 2025

Professor at Yonsei Severance; former head of the Yonsei Cancer Hospital gastric cancer centre

Jung Gil-young (정길영)

Outside director

In office at Mar 2026 AGM

NPD

Jeon Hyung-soo (전형수)

Outside director

In office at Mar 2026 AGM

NPD

Thomas Sager

CEO, Contera Pharma

Since about 2021

Former Lundbeck VP; more than 25 years in neurology

Søren Vestergaard Rasmussen

CSO, Contera Pharma

—

Presented CP-102 primate data, Apr 2026

Anne Birk Østerskov

CMO, Contera Pharma

—

Led CP-012 Phase 1b

Shareholding Trend

Shareholder (% of shares)Dec-2023Dec-2025

OCI Holdings Co., Ltd. (%)

10.9017.11

Kim Dong-yeon, co-founder (%)

9.937.15

Chung Chang-soo, co-founder / vice-chairman (%)

8.516.13

National Pension Service (%)

2.020.70

Foreign investors, aggregate (%)

4.335.89

Treasury shares (%)

3.670.00

Others / retail (%)

60.6463.02

Competitive Landscape

Peer Comparison FY2025

CompanyRevenue FY2025 (KRW 100M)Revenue growth (%)Operating profit (KRW 100M)Operating margin (%)R&D / sales (%)Market cap (KRW 100M, 2026)

Bukwang

2,00725.41427.113.04,100

Whanin Pharm

2,552-1.71305.1

NPD

1,867

Myungin Pharm

2,873

NPD

92532.2

NPD

NPD

Samjin Pharm

3,0910.32688.7

about 12 (Q1-26 12.2)

2,455

Myungmoon Pharm

1,9524.7683.5

NPD

413

Boryung

10,1740.06516.4

NPD

7,721

Recent Developments

Leadership changes in the period: Ahn Mi-jung became chairman (Mar 2025); the Union board was reconstituted (Jun–Jul 2026).

Company Snapshot

611

Employees

1960

Founded

SWOT Analysis

Strengths

  • Record scale. FY2025 revenue of KRW 200.7bn (+25.4%) and the first half-year above KRW 100bn (H1-26 KRW 104.8bn) [IR FY2025; Q2-26].
  • CNS momentum. CNS strategic products grew 91% in FY2025 against a 7.4% market; Latuda reached KRW 11.0bn in its first full year with 1,034 clinic accounts [IR FY2025].
  • Validated discovery platform. The Lundbeck collaboration (Oct 2025) is Contera's first global platform deal, with upfront, research funding, milestones and royalties [Lundbeck PR].
  • Net cash. About KRW 136bn net cash and a 40% liabilities-to-equity ratio at FY2025 year end [IR FY2025].
  • Committed sponsor. OCI has invested about KRW 173bn and holds 17.11% under a joint-management agreement [IR FY2025].
  • Shareholder-return credibility. KRW 12.3bn of dividends for FY2025 (about 98% payout) and high-dividend status; KRW 50bn of treasury shares cancelled in 2024 [Medigatenews; Medifonews].
  • Working-capital discipline. Receivable days fell from about 101 (FY2023) to about 51 (FY2025, derived) [Dailypharm; IR].

Weaknesses

  • Thin margins. H1-26 operating margin about 2.4%, versus 32% at Myungin [IR Q2-26; Dailypharm].
  • Capacity bottleneck. Ansan utilisation above 100% since 2023 (115% in Q1-26). About 20% of FY2025 revenue depended on outsourcing, and recurring stock-outs have hurt the business [Dailypharm May-2026; Dealsite Jun-2026].
  • Ageing plant. Ansan was built in 1985 with no fundamental renovation [Medifonews Mar-2025].
  • Legacy-brand stagnation. Q1-26 Thioctacid KRW 2.4bn versus KRW 3.3bn a year earlier; Legalon flat [Dealsite Jun-2026].
  • Costly R&D history. About KRW 120bn put into Contera, JM-010 failed, Protekt and Dyna wound down [Dealsite Jun-2026; Dailypharm May-2024].
  • Thin disclosure. No segment, capex or FCF data in IR, and inconsistent pre- and post-audit figures (FY2023 net loss of −415 vs −344).

Opportunities

  • Latuda MDD label. A Phase 3 IND is approved; success would widen the addressable market [Medigatenews Jul-2026].
  • CP-012 Phase 2. A first-in-class indication with no approved competitors; the company expects co-development or out-licensing on positive efficacy [KIRS; IR FY2025].
  • RNA NewCo. Spin-off and external VC funding could crystallise value; CP-102 out-licence potential [Dailypharm Apr-2026].
  • Unipharm synergies. Cephalosporin and injectables capability, about 30% more solid capacity, insourcing of outsourced products, and future CDMO revenue [IR FY2025; Dealsite Jun-2026].
  • Portfolio adjacencies. Servier co-promotion, Eroset, Budiang and Brivil broaden the chronic-disease and CNS baskets [Dailypharm 2026].
  • Possible OCI stake build. The 30% holding-company requirement by Sep 2027 could support the share price [TheGuru; Dealsite Jun-2026].

Threats

  • Clinical risk. CP-012 Phase 2 is a small (80-patient) study, and the JM-010 precedent shows Parkinson's trial difficulty [Dailypharm May-2024].
  • Pricing pressure. Korean price-cut reforms affect generics and IMDs (2026 debate).
  • Integration risk at Unipharm. Union was fully capital-impaired, was delisted, ran at 29% utilisation pre-deal, and its revenue had halved during rehabilitation [Dailypharm Nov/Dec-2025; HuffPost].
  • FX and input costs. These hit Q2-26 margins [MTN Jul-2026].
  • Specialist competition. Myungin and Whanin are expanding CNS lines; Whanin is pushing ADHD and non-CNS products [Dailypharm Feb-2026].
  • Sponsor risk. OCI Holdings' solar-business uncertainty could limit further support [TheGuru].

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
11 Apr 2025Amended rights-offering filing to the FSS (minority protection, OCI participation, market changes)Regulator-driven disclosure improvements
22 Apr 2025Q1-25: revenue KRW 47.8bn (+39%), operating profit KRW 3.0bn; Dexid/Thioctacid +234%Third straight profitable quarter
Q2 2025Ariplus (dementia combination) launchedNeurology expansion
May 2025Latuda monthly sales pass KRW 1bn; Big-5 hospitals codedCommercial traction
22 Jul 2025Q2-25: revenue KRW 42.6bn, operating profit KRW 2.1bn, net profit KRW 6.4bn (first in 15 quarters)Profitability confirmed
28 Jul 2025Rights-offering shares listed (KRW 89.3bn); OCI at 17.11%Balance sheet recapitalised
14 Aug 2025H1-2025 semi-annual report filedRoutine
17 Sep 2025CP-012 Phase 1b positive toplineClears the path to Phase 2
20 Oct 2025Contera–Lundbeck RNA collaborationExternal platform validation
21 Oct 2025Q3-25: revenue KRW 47.8bn (+12%), operating profit KRW 1.0bn (symposium costs); KRW 50 quarterly dividend declared (KRW 4.93bn)Dividends resume
Oct 2025Budiang (empagliflozin) launched; Circadeep (melatonin) scheduled for Q4Chronic-disease and CNS launches
18 Nov 2025Joint Bukwang–Contera IR; RNA NewCo plan announcedR&D restructuring
17 Dec 2025Conditional investment agreement to acquire Korea Union PharmCapacity strategy
5 Jan 2026Named final acquirer of Union (KRW 30bn; KRW 3bn deposit)—
9 Feb 2026FY2025 record: revenue KRW 200.7bn, operating profit KRW 14.1bnAll-time high
Mar 2026Bukwang Brivil launch symposium (14–15 Mar)Epilepsy entry
17–23 Mar 2026Servier co-promotion agreementCardiovascular portfolio
24 Mar 202666th AGM: 2030 top-20 vision; KRW 75 final DPS; high-dividend statusShares +13% intraday on 25 Mar (to about KRW 8,050)
Late Mar 2026Shares up 60% in one week and about 154% year to date (week of 23–27 Mar), linked to the RNA/Lundbeck narrative (Lundbeck's annual report highlighted the collaboration)Speculative peak, about KRW 9,890
3–6 Apr 2026KOSDAQ committee decides to delist Korea Union Pharm (improvement plan not met); Union files for an injunctionAcquisition proceeds regardless
21 Apr 2026Q1-26: revenue KRW 47.8bn (flat), operating profit KRW 1.1bn (−63%) on outsourced productionMargin pressure
22 Apr 2026CP-102 NHP data presentedPlatform credibility
12 May 2026Seoul Bankruptcy Court approves Union rehabilitation plan—
26 May 2026AI/organoid MOU with Dream CIS and AWSR&D productivity
27 May 2026KRW 30bn paid; Bukwang holds 75.14% of UnionDeal closed
2 Jun 2026Latuda MDD Phase 3 IND approval disclosedLifecycle extension
8 Jun 2026Shares at KRW 4,090, down more than 55% from the March peakVolatility
23 Jun 2026Union EGM replaces all 7 directors with 4 Bukwang nomineesIntegration
Jun 2026First Unipharm-made Bukwang product shipped (pancreatin combination)Synergy begins
Mid-2026CP-012 global Phase 2 IND filedClinical progression
21 Jul 2026Q2-26: revenue KRW 57.0bn (+34%), operating profit KRW 1.4bn (−30%); H1 revenue KRW 104.8bnFirst half-year above KRW 100bn
5 Aug 2026Eroset (pitavastatin/ezetimibe) launchedDyslipidaemia
13–14 Aug 2026H1-2026 report; Union applies to end rehabilitation (KRW 29.2bn of KRW 29.2bn claims repaid, except KRW 76M)—
31 Aug 2026Court concludes Union rehabilitation; Union debt ratio about 40% (about 15% excluding operating liabilities)De-risked subsidiary
8 Oct 2026Union renamed Bukwang UnipharmBrand integration

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

3 charts
Revenue by Segment (KRW): Consolidated revenue rose from KRW 1,825 in FY2021 to KRW 2,007 in FY2025.
Bukwang Pharmaceutical Co., Ltd. — Revenue by Segment (KRW)
Series (KRW)FY2021FY2022FY2023FY2024FY2025
Consolidated revenue1,8251,9091,2591,6012,007
Parent (separate) revenue1,8161,9031,2521,5761,673
Subsidiaries net of eliminations, revenue96725334
Parent operating profit132123-166170161
Consolidated operating profit56-2-36416141
Gap: subsidiaries' net operating drag-76-125-198-154-20

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Sources

Sources

  1. Bukwang IR Fact Book FY2025 (9 Feb 2026): file.alphasquare.co.kr/media/pdfs/company-ir/20260209부광약품_2025년_4분기_실적_및_R&D_진행사항.pdf
  2. Bukwang IR Q1 FY2026 (21 Apr 2026): file.alphasquare.co.kr/media/pdfs/company-ir/20260421부광약품_2026년_1분기_경영실적.pdf
  3. Bukwang IR Fact Book FY2023 (8 Feb 2024): files-scs.pstatic.net (2023년 4분기 팩트북)
  4. Bukwang IR H1-2025 and Q3-2025: IR 2Q2018 · IR 2022/2023 updates (alphasquare archive)
  5. KIND / Korea Exchange semi-annual report H1-2025 (66th FY)
  6. Korea IR Council (KIRS) company report, 2 Jun 2026 (stock.pstatic.net)
  7. Lundbeck/Contera press release, 20 Oct 2025 (mb.cision.com): The Pharma Letter · European Biotechnology · Nordic Life Science
  8. Trade press: Dailypharm, Dealsite, Medigatenews, Medifonews, Medicaltimes, Bizwatch, Kukinews, Kormedi, Biospectator, Edaily, Asiae, Sedaily, MTN, Newsis, HuffPost Korea, SBS Biz, Sateconomy, Dailian, TheGuru, IB Tomato, Sidae, CEOScore Daily, Newdaily
  9. Market data aggregators: butler.works, valueline.co.kr, StockHub, Paasa, Fintel, Simply Wall St, stoxray, Snowball Analytics, MarketVector (ISIN), IPqwery, financialfilings.com, SK Securities pharma weekly (Feb/Mar/May 2026)

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.